Advertisement
UK markets closed
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • CRUDE OIL

    82.79
    -0.57 (-0.68%)
     
  • GOLD FUTURES

    2,334.60
    -7.50 (-0.32%)
     
  • DOW

    38,466.80
    -36.89 (-0.10%)
     
  • Bitcoin GBP

    51,960.05
    -1,662.25 (-3.10%)
     
  • CMC Crypto 200

    1,397.83
    -26.27 (-1.84%)
     
  • NASDAQ Composite

    15,690.24
    -6.40 (-0.04%)
     
  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     

Thinking of Buying Novavax Stock? 3 Numbers You Should Look at First

Thinking of Buying Novavax Stock? 3 Numbers You Should Look at First

There's been lots of excitement surrounding Novavax (NASDAQ: NVAX). Cash burn is a big concern for a company such as Novavax, which is likely to see its revenue decline as demand for its COVID-19 vaccine dwindles. As of the end of March, the company had $625 million in cash and cash equivalents on the books -- down by more than half from more than $1.3 billion it reported at the end of 2022.